Figure S3 from &lt;i&gt;KRAS&lt;/i&gt; and &lt;i&gt;EGFR&lt;/i&gt; Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in &lt;i&gt;EGFR&lt;/i&gt;